Development of an Electronic Decision Aid Tool to Facilitate Mainstream Genetic Testing in Ovarian Cancer Patients

Author:

Shannon Kristen M1ORCID,Patel Devanshi1,Jonas Jessica M1,Blouch Erica L1,Hicks Stephanie R1ORCID,Wooters Mackenzie1,Seidel Meredith1,Grant Carly F1,Emmet Margaret M1,Chung Daniel C12,Sepucha Karen3

Affiliation:

1. Massachusetts General Hospital Center for Cancer Risk Assessment , Boston, MA , USA

2. Division of Gastroenterology, Massachusetts General Hospital , Boston, MA , USA

3. Health Decision Sciences Center, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA

Abstract

Abstract Background Multigene panel testing is an important component of cancer treatment plans and risk assessment, but there are many different panel options and choosing the most appropriate panel can be challenging for health care providers and patients. Electronic tools have been proposed to help patients make informed decisions about which gene panel to choose by considering their preferences and priorities. Materials and Methods An electronic decision aid (DA) tool was developed in line with the International Patient Decision Aids Standards collaboration. The multidisciplinary project team collaborated with an external health care communications agency and the MGH Cancer Center Patient and Family Advisory Council (PFAC) to develop the DA. Surveys of genetic counselors and patients were used to scope the content, and alpha testing was used to refine the design and content. Results Surveys of genetic counselors (n = 12) and patients (n = 228) identified common themes in discussing panel size and strategies for helping patients decide between panels and in identifying confusing terms for patients and distribution of patients’ choices. The DA, organized into 2 major sections, provides educational text, graphics, and videos to guide patients through the decision-making process. Alpha testing feedback from the PFAC (n = 4), genetic counselors (n = 3) and a group of lay people (n = 8) identified areas to improve navigation, simplify wording, and improve layout. Conclusion The DA developed in this study has the potential to facilitate informed decision-making by patients regarding cancer genetic testing. The distinctive feature of this DA is that it addresses the specific question of which multigene panel may be most suitable for the patient. Its acceptability and effectiveness will be evaluated in future studies.

Funder

AstraZeneca

Publisher

Oxford University Press (OUP)

Reference19 articles.

1. Informed consent for medical treatment and research: a review;del Carmen,2005

2. The future of parallel tumor and germline genetic testing: is there a role for all patients with cancer;Liu,2021

3. Universal germline genetic testing for hereditary cancer syndromes in patients with solid tumor cancer;Esplin,2022

4. The feasibility of implementing mainstream germline genetic testing in routine cancer care-a systematic review;Bokkers,2022

5. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients;George,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3